Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine

Critical Care Medicine

Volumn 31, Issue 4, 2003, Pages 1042-1047

  Claessens, Yann Erick ^a   Cariou, Alain ^a   Monchi, Mehran ^a   Soufir, Lilia ^b   Azoulay, Elie ^b   Rouges, Philippe ^c   Goldgran Toledano, Dany ^d   Branche, Fabienne ^e   Dhainaut, Jean François ^a  

^a Cochin Hospital ^*  (France)

^b SAINT LOUIS HOSPITAL   (France)

^c AVICENNE HOSPITAL   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e General Hospital   (France)

Author keywords

Acidosis; Human immunodeficiency virus; L carnitine; Lactate; Mitochondria; Nucleoside analog

Indexed keywords

ANTIVIRUS AGENT; CARNITINE; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; DRUG EFFICACY; EDEMA; FATIGUE; FEMALE; GENERAL HOSPITAL; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MALE; METEORISM; MORTALITY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PUBLICATION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STEATOSIS; SURVIVAL; TEACHING HOSPITAL;

ACIDOSIS, LACTIC; ADULT; ANTIVIRAL AGENTS; CARNITINE; FEMALE; HIV INFECTIONS; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SURVIVAL RATE;

EID: 0037387554     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000053649.69377.08     Document Type: Article

References (19)

1. Lewis W, Dalakas MC: Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417-422
2. Chariot P, Monnet I, Mouchet M, et al: Determination of the blood lactate:pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy. Arthritis Rheum 1994; 37:583-586
3. Lonergan JT, Behling C, Pfander H, et al: Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31:162-166
4. Fortgang IS, Belitsos PC, Chaisson RE, et al: Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995; 90:1433-1436
5. Sundar K, Suarez M, Banogon PE, et al: Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of literature. Crit Care Med 1997; 25:1425-1430
6. Claessens YE, Cariou A, Chiche JD, et al: L-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogs. AIDS 2000; 4:472-473
7. Brinkman K, Vrouenraets S, Kauffmann R, et al: Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 2000; 14:2801-2802
8. Semino-Mora MC, Leon-Monzon M, Dalakas M: The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II: Treatment with L-carnitine improves the AZT-induced changes and prevents further destruction. Lab Invest 1994; 71:773-781
9. Le Gall JR, Lemeshow S, Saulnier F: A new simplified acute physiologic score (SAPSII) based on a European-North American multicenter study. JAMA 1993; 270:29057-29068
10. Famularo G, Matricardi F, Nucera E, et al: Carnitine deficiency: Primary and secondary syndromes. In: Carnitine Today. De Simone C, Famularo G (Eds). Georgetown, TX, Landes Bioscience, 1997, pp 119-161.
11. De Simone C, Tzantzoglou S, Jirillo E, et al: L-Carnitine deficiency in AIDS patients. AIDS 1992; 6:203-205
12. Fouty B, Frerman F, Reves R: Riboflavin to treat nucleoside analogues-induced lactic acidosis. Lancet 1998; 352:291-292
13. Lenzo NP, Garas BA, French MA: Hepatic steatosis and lactic acidosis associated with stavudine treatment in a HIV patient: A case report. AIDS 1997; 11:1294-1296
14. Cowan BN, Burns HJ, Boyle P, et al: The relative prognostic value of lactate and haemodynamic measurements in early shock. Anaesthesia 1984; 39:750-755
15. Paumen MB, Ishida Y, Han H, et al: Direct interaction of the mitochondrial membrane protein carnitine palmitoyltransferase I with Bcl-2. Biochem Biophys Res Commun 1997; 231:523-525
16. Paumen MB, Ishida Y, Muramatsu M, et al: Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. J Biol Chem 1997; 272:3324-3329
17. Dalakas M, Leon-Monzon M, Bernardini I, et al: Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann Neurol 1994; 35:482-487
18. Brinkman K, Smeitink JA, Romijn JA, et al: Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115
19. Loignon M, Toma E: L-Carnitine for the treatment of highly active antiretroviral therapy-related hypertriglyceridemia in HIV-infected adults. AIDS 2001; 15: 1194-1195